$RARE
Ultragenyx Pharmaceutical Inc.

2017 Q4 Form 10-K Financial Statement

#000156459018002535 Filed on February 21, 2018

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017
Revenue $2.414M $198.0K $2.612M
YoY Change 48180.0% 78.38% 1863.91%
Cost Of Revenue $0.00 $1.000K
YoY Change
Gross Profit $2.410M $2.611M
YoY Change
Gross Profit Margin 99.83% 99.96%
Selling, General & Admin $37.72M $23.50M $99.91M
YoY Change 90.41% 36.78% 53.86%
% of Gross Profit 1565.15% 3826.46%
Research & Development $61.53M $60.41M $231.6M
YoY Change 21.24% 24.02% 26.44%
% of Gross Profit 2553.11% 8871.85%
Depreciation & Amortization $2.520M $1.090M $5.825M
YoY Change 119.13% 5.83% 70.12%
% of Gross Profit 104.56% 223.09%
Operating Expenses $99.25M $83.91M $331.6M
YoY Change 40.67% 27.34% 33.62%
Operating Profit -$96.84M -$328.9M
YoY Change 32.63%
Interest Expense $720.0K $1.120M $4.100M
YoY Change -20.88% 21.74% 7.89%
% of Operating Profit
Other Income/Expense, Net -$1.840M $3.370M $6.530M
YoY Change 13.58% -6840.0% 201.2%
Pretax Income -$97.95M -$79.22M -$318.3M
YoY Change 37.47% 22.05% 29.49%
Income Tax -$86.72M $4.000K -$16.20M
% Of Pretax Income
Net Earnings -$81.73M -$79.23M -$302.1M
YoY Change 14.65% 22.06% 22.88%
Net Earnings / Revenue -3385.71% -40013.64% -11567.34%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.894M -$1.866M -$7.108M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2017
SHORT-TERM ASSETS
Cash & Short-Term Investments $234.5M $371.1M $234.5M
YoY Change -38.31% -6.38% -38.31%
Cash & Equivalents $100.5M $60.41M $100.5M
Short-Term Investments $134.0M $310.7M $134.0M
Other Short-Term Assets $29.20M $19.90M $29.20M
YoY Change 35.81% -1.97% 35.81%
Inventory $757.0K $800.0K
Prepaid Expenses
Receivables $5.172M $5.200M
Other Receivables $0.00 $0.00
Total Short-Term Assets $269.6M $390.9M $269.6M
YoY Change -32.89% -6.21% -32.89%
LONG-TERM ASSETS
Property, Plant & Equipment $21.84M $16.00M $21.80M
YoY Change 28.04% -12.09% 27.49%
Goodwill $44.41M
YoY Change
Intangibles $141.5M
YoY Change
Long-Term Investments $10.00M $25.00M $10.00M
YoY Change -91.53% -67.19% -91.53%
Other Assets $3.407M $3.200M $3.400M
YoY Change 85.47% -17.95% -12.82%
Total Long-Term Assets $221.2M $44.10M $221.2M
YoY Change 59.19% -55.18% 59.25%
TOTAL ASSETS
Total Short-Term Assets $269.6M $390.9M $269.6M
Total Long-Term Assets $221.2M $44.10M $221.2M
Total Assets $490.8M $435.0M $490.8M
YoY Change -9.23% -15.57% -9.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.886M $9.300M $8.900M
YoY Change 65.66% 40.91% 64.81%
Accrued Expenses $62.13M $54.30M $61.40M
YoY Change 13.88% 24.83% 12.45%
Deferred Revenue $5.986M
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $71.01M $64.30M $71.00M
YoY Change 17.85% 27.58% 17.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $5.119M $5.200M $5.100M
YoY Change -19.93% -40.91% -20.31%
Total Long-Term Liabilities $5.119M $5.200M $5.100M
YoY Change -19.93% -40.91% -20.31%
TOTAL LIABILITIES
Total Short-Term Liabilities $71.01M $64.30M $71.00M
Total Long-Term Liabilities $5.119M $5.200M $5.100M
Total Liabilities $107.3M $69.50M $107.3M
YoY Change 60.98% 17.2% 60.87%
SHAREHOLDERS EQUITY
Retained Earnings -$832.7M
YoY Change 56.95%
Common Stock $44.00K
YoY Change 7.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $383.5M $365.6M $383.5M
YoY Change
Total Liabilities & Shareholders Equity $490.8M $435.0M $490.8M
YoY Change -9.23% -15.57% -9.21%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017
OPERATING ACTIVITIES
Net Income -$81.73M -$79.23M -$302.1M
YoY Change 14.65% 22.06% 22.88%
Depreciation, Depletion And Amortization $2.520M $1.090M $5.825M
YoY Change 119.13% 5.83% 70.12%
Cash From Operating Activities -$81.82M -$61.99M -$253.8M
YoY Change 71.6% 115.62% 57.69%
INVESTING ACTIVITIES
Capital Expenditures -$900.0K -$1.030M $2.793M
YoY Change 34.33% -65.67% -72.59%
Acquisitions $142.8M
YoY Change
Other Investing Activities $57.07M $30.83M $58.28M
YoY Change -980.71% -44.46% -42.47%
Cash From Investing Activities $56.17M $29.79M $55.48M
YoY Change -885.59% -43.27% -39.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 64.44M 1.330M 136.3M
YoY Change -14.01% -97.9% -1.74%
NET CHANGE
Cash From Operating Activities -81.82M -61.99M -253.8M
Cash From Investing Activities 56.17M 29.79M 55.48M
Cash From Financing Activities 64.44M 1.330M 136.3M
Net Change In Cash 38.79M -30.87M -61.57M
YoY Change 92.89% -135.4% -189.55%
FREE CASH FLOW
Cash From Operating Activities -$81.82M -$61.99M -$253.8M
Capital Expenditures -$900.0K -$1.030M $2.793M
Free Cash Flow -$80.92M -$60.96M -$256.6M
YoY Change 72.13% 136.74% 49.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
184945000
CY2017Q4 us-gaap Inventory Net
InventoryNet
757000
CY2017Q4 us-gaap Goodwill
Goodwill
44406000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1315000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1837000
CY2017Q4 us-gaap Assets
Assets
490753000
CY2016Q4 us-gaap Assets
Assets
540626000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
8886000
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5364000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
61427000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
701000
CY2016Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
341000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1221762000
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5680000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
383454000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
490753000
CY2017 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-10110000
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
35000
CY2017 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6585000
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6530000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-318338000
CY2016 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-4842000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
183204000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
114737000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1411000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5172000
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20136000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
99909000
CY2017 us-gaap Operating Expenses
OperatingExpenses
331554000
CY2016 us-gaap Operating Expenses
OperatingExpenses
248140000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-328942000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-248007000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-147738000
CY2017 us-gaap Investment Income Interest
InvestmentIncomeInterest
4074000
CY2016 us-gaap Investment Income Interest
InvestmentIncomeInterest
3789000
CY2015 us-gaap Investment Income Interest
InvestmentIncomeInterest
2320000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-200000
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17055000
CY2016Q4 us-gaap Assets Current
AssetsCurrent
401695000
CY2016Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
2076000
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
54554000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5119000
CY2017Q4 us-gaap Liabilities
Liabilities
107299000
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-832672000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000
CY2017 rare Collaboration And License Revenue
CollaborationAndLicenseRevenue
2136000
CY2017 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
476000
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
133000
CY2017 us-gaap Sales Revenue Net
SalesRevenueNet
2612000
CY2016 us-gaap Sales Revenue Net
SalesRevenueNet
133000
CY2017 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
231644000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
64936000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
33001000
CY2015 us-gaap Operating Expenses
OperatingExpenses
147738000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1621000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-245839000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-145618000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-16199000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-302139000
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-7.12
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-6.21
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.96
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
42453135
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39586908
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
36782603
CY2016 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1322000
CY2017 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment From Aoci Realized Upon Sale Or Liquidation Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax
-3490000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44167071
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44167071
CY2017 rare Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
131960000
CY2016 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
48309000
CY2015 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24884000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1773000
CY2016 rare Stock Issued During Period Value At Market Offering
StockIssuedDuringPeriodValueAtMarketOffering
79486000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-694000
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-308724000
CY2015 rare Stock Issued During Period Value Secondary Issues
StockIssuedDuringPeriodValueSecondaryIssues
461136000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-244101000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-146312000
CY2016 rare Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
79486000
CY2016 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
51356000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24884000
CY2015 rare Issuance Of Common Stock Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax
6437000
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
531090000
CY2016 rare Stock Issued During Period Value For Collaboration Agreement
StockIssuedDuringPeriodValueForCollaborationAgreement
52272000
CY2016 rare Adjustments To Additional Paid In Capital Put Option Grant For Collaboration Agreement
AdjustmentsToAdditionalPaidInCapitalPutOptionGrantForCollaborationAgreement
-916000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
48309000
CY2016 rare Issuance Of Common Stock Under Equity Plan Awards Net Of Tax
IssuanceOfCommonStockUnderEquityPlanAwardsNetOfTax
7834000
CY2017 rare Stock Issued During Period Value At Market Offering
StockIssuedDuringPeriodValueAtMarketOffering
131960000
CY2017 rare Fair Value Of Vested Stock Options Assumed From Acquisition
FairValueOfVestedStockOptionsAssumedFromAcquisition
8979000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
68014000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
48309000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
24884000
CY2017 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1706000
CY2015 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-5637000
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5825000
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3424000
CY2015 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1384000
CY2017 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
7018000
CY2016 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-1322000
CY2016 rare Noncash License Fee From Collaboration Arrangement
NoncashLicenseFeeFromCollaborationArrangement
700000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3338000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7147000
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-522000
CY2016 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
1242000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3459000
CY2016 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2502000
CY2017 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4628000
CY2016 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
32189000
CY2017 rare Increase Decrease In Deferred Tax Liabilities
IncreaseDecreaseInDeferredTaxLiabilities
-16246000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-253843000
CY2017 us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
142804000
CY2015 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
89321000
CY2015 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
249050000
CY2015 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
1541000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-79227000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-292351000
CY2017 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
9251000
CY2016 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
7834000
CY2015 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
6437000
CY2017 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
4944000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
136267000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
138676000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
467573000
CY2017 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
528000
CY2016 us-gaap Effect Of Exchange Rate On Cash Continuing Operations
EffectOfExchangeRateOnCashContinuingOperations
-65000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-60632000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
67551000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
69245000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
93569000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24324000
CY2017 rare Fair Value Of Vested Stock Options Assumed In Acquisition
FairValueOfVestedStockOptionsAssumedInAcquisition
8979000
CY2017 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
400000
CY2016 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
147000
CY2015 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
769000
CY2016 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
3467000
CY2017 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:13pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:4pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities and the reported amounts of expenses in the consolidated financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to clinical trial accruals, fair value of assets and liabilities, income taxes, and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. </p></div>
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
130037
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3826963
CY2017 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2017 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
18528000
CY2016 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
12684000
CY2017 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
341737000
CY2016 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
306596000
CY2017Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
223649000
CY2016Q4 us-gaap Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
482876000
CY2017Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
224029000
CY2017Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
380000
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
223649000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
483293000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
27000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
444000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
482876000
CY2017 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
737000
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
20000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
32828000
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23216000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
10991000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6161000
CY2017 rare Depreciation Excluding Intangible Amortization
DepreciationExcludingIntangibleAmortization
4800000
CY2016 rare Depreciation Excluding Intangible Amortization
DepreciationExcludingIntangibleAmortization
3400000
CY2015 rare Depreciation Excluding Intangible Amortization
DepreciationExcludingIntangibleAmortization
1400000
CY2017Q4 rare Research And Clinical Trial Expenses
ResearchAndClinicalTrialExpenses
17141000
CY2016Q4 rare Research And Clinical Trial Expenses
ResearchAndClinicalTrialExpenses
18593000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
26527000
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17226000
CY2017Q4 rare Liability Under Collaboration Arrangement
LiabilityUnderCollaborationArrangement
3681000
CY2016Q4 rare Liability Under Collaboration Arrangement
LiabilityUnderCollaborationArrangement
13650000
CY2017Q4 rare Contract Liability
ContractLiability
5986000
CY2017Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
8092000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5085000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2739475
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2013350
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
795825
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1435995
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
425922
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
407564
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4429472
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1328860
CY2017 rare Share Based Compensation Arrangement By Share Based Payment Award Options Assumed In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInPeriod
639897
CY2017 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
478470
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
520349
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5399410
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2709510
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
5216110
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.15
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
90.60
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.65
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
31.49
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
56.36
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
67.00
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
21.21
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
70.87
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
61.85
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
71.99
CY2017 rare Share Based Compensation Arrangements By Share Based Payment Award Options Assumed In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedInPeriodWeightedAverageExercisePrice
27.97
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
16.25
CY2017 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
78.70
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
62.75
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
53.53
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
62.50
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M4D
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y6M29D
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M19D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M24D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M19D
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y4M6D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
79840000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
217386000
CY2017 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.090
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.014
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
79135000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
37687000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
34558000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
37528000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
20400000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
22200000
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
59000000
CY2017 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7800000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9000000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6900000
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
44.20
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
40.49
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
54.90
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
49100000
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
43800000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
10700000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
68014000
CY2017Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
165300000
CY2017 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y6M7D
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
2100000
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1500000
CY2015 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
600000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-250917000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-192287000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-145618000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-67421000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-53552000
CY2017 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
5000
CY2017 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
42000
CY2016 us-gaap Foreign Income Tax Expense Benefit Continuing Operations
ForeignIncomeTaxExpenseBenefitContinuingOperations
35000
CY2017 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
47000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
35000
CY2017 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-16243000
CY2017 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-3000
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-16246000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.013
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.075
CY2016 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.137
CY2015 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.059
CY2017 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.009
CY2016 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
-0.003
CY2015 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.008
CY2017 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.006
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.013
CY2017 rare Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions
EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
-0.018
CY2016 rare Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions
EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
0.020
CY2015 rare Effective Income Tax Rate Reconciliation Change In Uncertain Tax Positions
EffectiveIncomeTaxRateReconciliationChangeInUncertainTaxPositions
-0.077
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.325
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.419
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.392
CY2017 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.072
CY2017Q4 rare Deferred Tax Assets Stock Option
DeferredTaxAssetsStockOption
21336000
CY2016 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.074
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.051
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
69954000
CY2017 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.051
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
154949000
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
102960000
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
119542000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
78324000
CY2017Q4 us-gaap Contractual Obligation
ContractualObligation
8828000
CY2017Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
2414000
CY2016Q4 rare Deferred Tax Assets Stock Option
DeferredTaxAssetsStockOption
16084000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
5939000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
10039000
CY2017Q4 rare Deferred Tax Asset Fixed Assets And Intangibles
DeferredTaxAssetFixedAssetsAndIntangibles
1194000
CY2016Q4 rare Deferred Tax Asset Fixed Assets And Intangibles
DeferredTaxAssetFixedAssetsAndIntangibles
3014000
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1286000
CY2016Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1950000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
304246000
CY2016Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
212371000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
304246000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
212371000
CY2017Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
31166000
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
200000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
200000
CY2017 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-16200000
CY2017 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
70500000
CY2017 rare Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
16100000
CY2017 rare Tax Cuts And Jobs Act Of2017 Change In Valuation Allowance
TaxCutsAndJobsActOf2017ChangeInValuationAllowance
86600000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
13505000
CY2015Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
24010000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7275000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
9338000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
6777000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
15628000
CY2017 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
5534000
CY2016 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
877000
CY2015 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
5505000
CY2016 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
18159000
CY2015 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
4398000
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2016Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
4500000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
6210000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
5293000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3727000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2477000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2413000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
9033000
CY2017Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
29153000
CY2017Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
7542000
CY2017Q4 us-gaap Contractual Obligation Due In Second Year
ContractualObligationDueInSecondYear
1224000
CY2017Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
62000
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6015212
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4856744
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3564269
CY2017Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
198000
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
78441000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
83911000
CY2017Q4 us-gaap Operating Expenses
OperatingExpenses
99248000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-68290000
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-72891000
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-81731000
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.89
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
17000
CY2016Q3 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
111000
CY2016Q4 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
5000
CY2016Q4 us-gaap Operating Expenses
OperatingExpenses
70554000
CY2016Q4 us-gaap Net Income Loss
NetIncomeLoss
-71287000

Files In Submission

Name View Source Status
0001564590-18-002535-index-headers.html Edgar Link pending
0001564590-18-002535-index.html Edgar Link pending
0001564590-18-002535.txt Edgar Link pending
0001564590-18-002535-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g201802210545485485979.jpg Edgar Link pending
g201802210545491225515.jpg Edgar Link pending
g201802210546029934405.jpg Edgar Link pending
g201802210546040554834.jpg Edgar Link pending
g201802210546040564835.jpg Edgar Link pending
g201802210546149914905.jpg Edgar Link pending
g201802210546156064406.jpg Edgar Link pending
g201802210546188204905.jpg Edgar Link pending
g201802210546259864814.jpg Edgar Link pending
g201802210546263234815.jpg Edgar Link pending
g201802210546263394816.jpg Edgar Link pending
g201802210546264434817.jpg Edgar Link pending
g201802210546264624818.jpg Edgar Link pending
g201802210546264824819.jpg Edgar Link pending
g201802210546265034820.jpg Edgar Link pending
g201802210546265264821.jpg Edgar Link pending
g201802210547249854836.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rare-10k_20171231.htm Edgar Link pending
rare-20171231.xml Edgar Link completed
rare-20171231.xsd Edgar Link pending
rare-20171231_cal.xml Edgar Link unprocessable
rare-20171231_def.xml Edgar Link unprocessable
rare-20171231_lab.xml Edgar Link unprocessable
rare-20171231_pre.xml Edgar Link unprocessable
rare-ex1011_421.htm Edgar Link pending
rare-ex1013_422.htm Edgar Link pending
rare-ex1014_420.htm Edgar Link pending
rare-ex1015_418.htm Edgar Link pending
rare-ex1016_417.htm Edgar Link pending
rare-ex1017_426.htm Edgar Link pending
rare-ex1018_869.htm Edgar Link pending
rare-ex1019_867.htm Edgar Link pending
rare-ex1031_416.htm Edgar Link pending
rare-ex1032_415.htm Edgar Link pending
rare-ex103_423.htm Edgar Link pending
rare-ex1046_1375.htm Edgar Link pending
rare-ex104_871.htm Edgar Link pending
rare-ex105_868.htm Edgar Link pending
rare-ex1060_866.htm Edgar Link pending
rare-ex1061_414.htm Edgar Link pending
rare-ex1062_413.htm Edgar Link pending
rare-ex1063_412.htm Edgar Link pending
rare-ex1064_410.htm Edgar Link pending
rare-ex1065_409.htm Edgar Link pending
rare-ex1066_411.htm Edgar Link pending
rare-ex211_408.htm Edgar Link pending
rare-ex22_424.htm Edgar Link pending
rare-ex231_13.htm Edgar Link pending
rare-ex311_16.htm Edgar Link pending
rare-ex312_15.htm Edgar Link pending
rare-ex321_12.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending